Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16412923 | 1.00 | EPHX1 (0.36) | EPHX1TRPM8MAPTALDH1A1HPGD | |
| SCHEMBL14742726 | 1.00 | EPHX1 (0.36) | EPHX1TRPM8MAPTALDH1A1HPGD | |
| SCHEMBL560313 | 0.82 | CHRM2 (0.38) | EPHX1CES2TSHR | |
| SCHEMBL12604928 | 0.82 | EPHX1 (0.37) | EPHX1TRPM8ALDH1A1HPGDCYP19A1 | |
| SCHEMBL560314 | 0.82 | CHRM2 (0.38) | EPHX1CES2TSHR | |
| SCHEMBL16412379 | 0.81 | CYP19A1 (0.41) | EPHX1TRPM8MAPTALDH1A1HPGD | |
| SCHEMBL14742826 | 0.81 | CYP19A1 (0.41) | EPHX1TRPM8MAPTALDH1A1HPGD | |
| SCHEMBL25990013 | 0.78 | TRPM8 (0.39) | EPHX1TRPM8MAPTALDH1A1CYP19A1 | |
| SCHEMBL12604937 | 0.78 | EPHX1 (0.54) | EPHX1TRPM8MAPTALDH1A1HPGD | |
| SCHEMBL23196361 | 0.78 | EPHX1 (0.57) | EPHX1TRPM8MAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11528933-B2 | Smoking article | NICO VENTURES TRADING LIMITED (GB) | 2022-12-20 | — | — | US | disclosed |
| EP-3262955-A2 | NOVEL SUBSTITUTED CYCLOHEXANE COMPOUNDS | Takasago International Corporation (USA) (US) | 2018-01-03 | — | — | EP | disclosed |
| US-9802885-B2 | Substituted cyclohexane compounds | TAKASAGO INTERNATIONAL CORPORATION (USA) (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150030744-A1 | NOVEL SUBSTITUTED CYCLOHEXANE COMPOUNDS | TAKASAGO INTERNATIONAL CORP. (USA) (US) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150030744-A1 | NOVEL SUBSTITUTED CYCLOHEXANE COMPOUNDS | TAS2R1, TAS2R8, TAS2R13 | EPHX1 2170/4885TRPM8 435/4885MAPT 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.